Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genzyme Chemical Unit Goes To ICIG
by Michael McCoy
February 7, 2011
| A version of this story appeared in
Volume 89, Issue 6
Genzyme has agreed to sell its pharmaceutical intermediates business to International Chemical Investors Group for an undisclosed sum. The business, in Liestal, Switzerland, makes chemically synthesized lipids, peptides, carbohydrates, and oligonucleotides. Under the deal, ICIG will supply Genzyme with materials needed to make eliglustat tartrate, a Genzyme drug in Phase III clinical trials for Gaucher’s disease, as well as other in-development treatments. In recent years, ICIG has purchased fine chemicals assets from AstraZeneca, Bristol-Myers Squibb, Cambrex, Rütgers, Clariant, and others.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter